BridgeBio Pharma, Inc.
BBIO
$68.55
$2.603.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.02% | 27.24% | -12.78% | -147.64% | -375.41% |
| Total Depreciation and Amortization | -7.63% | 4.97% | -9.10% | -16.33% | -19.55% |
| Total Amortization of Deferred Charges | 12.21% | -29.69% | -16.37% | -- | -- |
| Total Other Non-Cash Items | 8.66% | 57.36% | 405.25% | 180.60% | 107.34% |
| Change in Net Operating Assets | -7.38% | 283.24% | -83.52% | -92.12% | 48.42% |
| Cash from Operations | 0.98% | 71.11% | 39.32% | -208.00% | 9.25% |
| Capital Expenditure | -- | 29.79% | -243.07% | -1,000.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,574.98% | -348.93% | -87.15% | -488.84% | -106.80% |
| Cash from Investing | -2,579.31% | -343.44% | -88.32% | -527.84% | -107.01% |
| Total Debt Issued | 10.00% | -100.00% | -- | -- | 27.78% |
| Total Debt Repaid | -- | -- | -- | -- | 3.05% |
| Issuance of Common Stock | 387.24% | 363.90% | 273.02% | -- | -98.19% |
| Repurchase of Common Stock | -72.97% | -429.20% | -109.63% | 0.10% | -1,604.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -111.72% | 71.05% | -- | 16.32% | 7.15% |
| Cash from Financing | 811.50% | -100.46% | -226.45% | 5,372.14% | -78.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 320.55% | -126.49% | 25.16% | 189.33% | -269.76% |